U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Nephropathy due to Cisplatin

MedGen UID:
881442
•Concept ID:
C4054403
•
Disease or Syndrome

Definition

Kidney damage resulting from cisplatin. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVNephropathy due to Cisplatin

Professional guidelines

PubMed

Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.
Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Valderrabano F
Nephrol Dial Transplant 1996;11 Suppl 7:4-20. doi: 10.1093/ndt/11.supp7.4. PMID: 9067983

Recent clinical studies

Etiology

Conventional Chemotherapy Nephrotoxicity.
Gupta S, Portales-Castillo I, Daher A, Kitchlu A
Adv Chronic Kidney Dis 2021 Sep;28(5):402-414.e1. doi: 10.1053/j.ackd.2021.08.001. PMID: 35190107
Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.
Jagieła J, Bartnicki P, Rysz J
Int J Mol Sci 2021 Apr 28;22(9) doi: 10.3390/ijms22094618. PMID: 33924827Free PMC Article
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.
Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, Blais N, Sridhar SS
Nat Rev Urol 2021 Feb;18(2):104-114. Epub 2021 Jan 11 doi: 10.1038/s41585-020-00404-6. PMID: 33432181
Hesperetin relieves cisplatin-induced acute kidney injury by mitigating oxidative stress, inflammation and apoptosis.
Chen X, Wei W, Li Y, Huang J, Ci X
Chem Biol Interact 2019 Aug 1;308:269-278. Epub 2019 May 31 doi: 10.1016/j.cbi.2019.05.040. PMID: 31153982
Anti-cancer agent-induced nephrotoxicity.
Fukasawa H, Furuya R, Yasuda H, Yamamoto T, Hishida A, Kitagawa M
Anticancer Agents Med Chem 2014;14(7):921-7. doi: 10.2174/1871520614666140127105809. PMID: 24476314

Diagnosis

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P
Eur Urol 2023 Jul;84(1):49-64. Epub 2023 Mar 24 doi: 10.1016/j.eururo.2023.03.013. PMID: 36967359
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.
Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, Blais N, Sridhar SS
Nat Rev Urol 2021 Feb;18(2):104-114. Epub 2021 Jan 11 doi: 10.1038/s41585-020-00404-6. PMID: 33432181
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.
Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Cowan NC, Dominguez-Escrig JL, Gontero P, Hugh Mostafid A, Palou J, Peyronnet B, Seisen T, Soukup V, Sylvester RJ, Rhijn BWGV, Zigeuner R, Shariat SF
Eur Urol 2021 Jan;79(1):62-79. Epub 2020 Jun 24 doi: 10.1016/j.eururo.2020.05.042. PMID: 32593530
Drug-induced nephrotoxicity.
Sales GTM, Foresto RD
Rev Assoc Med Bras (1992) 2020 Jan 13;66Suppl 1(Suppl 1):s82-s90. doi: 10.1590/1806-9282.66.S1.82. PMID: 31939540
Drug-induced renal Fanconi syndrome.
Hall AM, Bass P, Unwin RJ
QJM 2014 Apr;107(4):261-9. Epub 2013 Dec 24 doi: 10.1093/qjmed/hct258. PMID: 24368854

Therapy

Natural products: potential treatments for cisplatin-induced nephrotoxicity.
Fang CY, Lou DY, Zhou LQ, Wang JC, Yang B, He QJ, Wang JJ, Weng QJ
Acta Pharmacol Sin 2021 Dec;42(12):1951-1969. Epub 2021 Mar 9 doi: 10.1038/s41401-021-00620-9. PMID: 33750909Free PMC Article
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.
Jiang DM, Gupta S, Kitchlu A, Meraz-Munoz A, North SA, Alimohamed NS, Blais N, Sridhar SS
Nat Rev Urol 2021 Feb;18(2):104-114. Epub 2021 Jan 11 doi: 10.1038/s41585-020-00404-6. PMID: 33432181
Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury.
Holditch SJ, Brown CN, Lombardi AM, Nguyen KN, Edelstein CL
Int J Mol Sci 2019 Jun 20;20(12) doi: 10.3390/ijms20123011. PMID: 31226747Free PMC Article
Pathophysiology of cisplatin-induced acute kidney injury.
Ozkok A, Edelstein CL
Biomed Res Int 2014;2014:967826. Epub 2014 Aug 6 doi: 10.1155/2014/967826. PMID: 25165721Free PMC Article
Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.
Pabla N, Dong Z
Kidney Int 2008 May;73(9):994-1007. Epub 2008 Feb 13 doi: 10.1038/sj.ki.5002786. PMID: 18272962

Prognosis

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P
Eur Urol 2023 Jul;84(1):49-64. Epub 2023 Mar 24 doi: 10.1016/j.eururo.2023.03.013. PMID: 36967359
Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel.
Wang H, Guo S, Kim SJ, Shao F, Ho JWK, Wong KU, Miao Z, Hao D, Zhao M, Xu J, Zeng J, Wong KH, Di L, Wong AH, Xu X, Deng CX
Theranostics 2021;11(5):2442-2459. Epub 2021 Jan 1 doi: 10.7150/thno.46460. PMID: 33500735Free PMC Article
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.
Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Cowan NC, Dominguez-Escrig JL, Gontero P, Hugh Mostafid A, Palou J, Peyronnet B, Seisen T, Soukup V, Sylvester RJ, Rhijn BWGV, Zigeuner R, Shariat SF
Eur Urol 2021 Jan;79(1):62-79. Epub 2020 Jun 24 doi: 10.1016/j.eururo.2020.05.042. PMID: 32593530
Drug-induced renal Fanconi syndrome.
Hall AM, Bass P, Unwin RJ
QJM 2014 Apr;107(4):261-9. Epub 2013 Dec 24 doi: 10.1093/qjmed/hct258. PMID: 24368854
Cisplatin nephrotoxicity.
Arany I, Safirstein RL
Semin Nephrol 2003 Sep;23(5):460-4. doi: 10.1016/s0270-9295(03)00089-5. PMID: 13680535

Clinical prediction guides

Gastrodin alleviates cisplatin nephrotoxicity by inhibiting ferroptosis via the SIRT1/FOXO3A/GPX4 signaling pathway.
Qiu CW, Chen B, Zhu HF, Liang YL, Mao LS
J Ethnopharmacol 2024 Jan 30;319(Pt 3):117282. Epub 2023 Oct 5 doi: 10.1016/j.jep.2023.117282. PMID: 37802374
The transcription factor Fosl1 preserves Klotho expression and protects from acute kidney injury.
Cuarental L, Ribagorda M, Ceballos MI, Pintor-Chocano A, Carriazo SM, Dopazo A, Vazquez E, Suarez-Alvarez B, Cannata-Ortiz P, Sanz AB, Ortiz A, Sanchez-Niño MD
Kidney Int 2023 Apr;103(4):686-701. Epub 2022 Dec 22 doi: 10.1016/j.kint.2022.11.023. PMID: 36565807
Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.
Guo X, Xu L, Velazquez H, Chen TM, Williams RM, Heller DA, Burtness B, Safirstein R, Desir GV
J Am Soc Nephrol 2022 Feb;33(2):342-356. Epub 2021 Dec 17 doi: 10.1681/ASN.2021040439. PMID: 34921111Free PMC Article
VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis.
Hu Z, Zhang H, Yi B, Yang S, Liu J, Hu J, Wang J, Cao K, Zhang W
Cell Death Dis 2020 Jan 29;11(1):73. doi: 10.1038/s41419-020-2256-z. PMID: 31996668Free PMC Article
Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule.
Deng F, Sharma I, Dai Y, Yang M, Kanwar YS
J Clin Invest 2019 Nov 1;129(11):5033-5049. doi: 10.1172/JCI129903. PMID: 31437128Free PMC Article

Recent systematic reviews

Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.
Sikking C, Niggebrugge-Mentink KL, van der Sman ASE, Smit RHP, Bouman-Wammes EW, Beex-Oosterhuis MM, van Kesteren C
Oncologist 2024 Feb 2;29(2):e173-e186. doi: 10.1093/oncolo/oyad297. PMID: 37995306Free PMC Article
Long-term cisplatin nephrotoxicity after childhood cancer: a systematic review and meta-analysis.
Schofield J, Harcus M, Pizer B, Jorgensen A, McWilliam S
Pediatr Nephrol 2024 Mar;39(3):699-710. Epub 2023 Sep 20 doi: 10.1007/s00467-023-06149-9. PMID: 37726572Free PMC Article
Dysregulated MicroRNAs as Biomarkers or Therapeutic Targets in Cisplatin-Induced Nephrotoxicity: A Systematic Review.
de Godoy Torso N, Pereira JKN, Visacri MB, Vasconcelos PENS, Loren P, Saavedra K, Saavedra N, Salazar LA, Moriel P
Int J Mol Sci 2021 Nov 25;22(23) doi: 10.3390/ijms222312765. PMID: 34884570Free PMC Article
Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity.
Casanova AG, Hernández-Sánchez MT, López-Hernández FJ, Martínez-Salgado C, Prieto M, Vicente-Vicente L, Morales AI
Eur J Clin Pharmacol 2020 Jan;76(1):23-33. Epub 2019 Nov 1 doi: 10.1007/s00228-019-02771-5. PMID: 31677116
A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J
Eur Urol 2014 Sep;66(3):529-41. Epub 2014 Mar 16 doi: 10.1016/j.eururo.2014.03.003. PMID: 24680361

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...